TY - JOUR
T1 - Unveiling the impact of circulating tumor cells
T2 - Two decades of discovery and clinical advancements in solid tumors
AU - On behalf of the International Society of Liquid Biopsy (ISLB)
AU - Reduzzi, Carolina
AU - Nicolo’, Eleonora
AU - Singhal, Surbhi
AU - Venetis, Konstantinos
AU - Ortega-Franco, Ana
AU - de Miguel-Perez, Diego
AU - Dipasquale, Angelo
AU - Gouda, Mohamed A.
AU - Saldanha, Erick F.
AU - Kasi, Pashtoon M.
AU - Jantus-Lewintre, Eloisa
AU - Fusco, Nicola
AU - Malapelle, Umberto
AU - Gandara, David R.
AU - Rolfo, Christian
AU - Serrano, Maria Jose
AU - Cristofanilli, Massimo
N1 - Publisher Copyright:
© 2024 Elsevier B.V.
PY - 2024/11
Y1 - 2024/11
N2 - Circulating tumor cells (CTCs) enumeration and molecular profiling hold promise in revolutionizing the management of solid tumors. Their understanding has evolved significantly over the past two decades, encompassing pivotal biological discoveries and clinical studies across various malignancies. While for some tumor types, such as breast, prostate, and colorectal cancer, CTCs are ready to enter clinical practice, for others, additional research is required. CTCs serve as versatile biomarkers, offering insights into tumor biology, metastatic progression, and treatment response. This review summarizes the latest advancements in CTC research and highlights future directions of investigation. Special attention is given to concurrent evaluations of CTCs and other circulating biomarkers, particularly circulating tumor DNA. Multi-analyte assessment holds the potential to unlock the full clinical capabilities of liquid biopsy. In conclusion, CTCs represent a transformative biomarker in precision oncology, offering extraordinary opportunities to translate scientific discoveries into tangible improvements in patient care.
AB - Circulating tumor cells (CTCs) enumeration and molecular profiling hold promise in revolutionizing the management of solid tumors. Their understanding has evolved significantly over the past two decades, encompassing pivotal biological discoveries and clinical studies across various malignancies. While for some tumor types, such as breast, prostate, and colorectal cancer, CTCs are ready to enter clinical practice, for others, additional research is required. CTCs serve as versatile biomarkers, offering insights into tumor biology, metastatic progression, and treatment response. This review summarizes the latest advancements in CTC research and highlights future directions of investigation. Special attention is given to concurrent evaluations of CTCs and other circulating biomarkers, particularly circulating tumor DNA. Multi-analyte assessment holds the potential to unlock the full clinical capabilities of liquid biopsy. In conclusion, CTCs represent a transformative biomarker in precision oncology, offering extraordinary opportunities to translate scientific discoveries into tangible improvements in patient care.
KW - Cancer
KW - Circulating tumor DNA
KW - Circulating tumor cells
KW - Liquid biopsy
KW - Precision medicine
KW - Prognosis
KW - Solid tumors
KW - Tumor biology
UR - https://www.scopus.com/pages/publications/85201687782
U2 - 10.1016/j.critrevonc.2024.104483
DO - 10.1016/j.critrevonc.2024.104483
M3 - Review article
C2 - 39159706
AN - SCOPUS:85201687782
SN - 1040-8428
VL - 203
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
M1 - 104483
ER -